Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer

Next Previous
X
Search
Trial Profile

An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ZACTIMA 58; ZETA
  • Sponsors AstraZeneca; Sanofi Genzyme

    • Most Recent Events

    • 22 Sep 2023 Planned End Date changed from 29 Dec 2023 to 28 Jun 2024.
    • 03 Oct 2022 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
    • 05 May 2022 The trial has been completed in Hungary, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top